Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)

被引：0
|
作者：
Govindarajan, R.
Siegel, E.
Makhoul, I.
Williamson, S.
机构：
[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15557
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
    Zhao, Chuanhua
    Lin, Li
    Liu, Jianzhi
    Liu, Rongrui
    Chen, Yuling
    Ge, Feijiao
    Jia, Ru
    Jin, Yang
    Wang, Yan
    Xu, Jianming
    ONCOTARGET, 2016, 7 (35) : 57310 - 57316
  • [22] A phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in patients with advanced hepatocellular carcinoma (HCC)
    Knox, Jennifer J.
    Qin, Rui
    Strosberg, Jonathan R.
    Kaubisch, Andreas
    El-Khoueiry, Anthony B.
    Bekaii-Saab, Tanios B.
    Erlichman, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study
    Hsu, Chih-Hung
    Kang, Yoon Koo
    Yang, Tsai-Shen
    Shun, Chia-Tung
    Shao, Yu-Yun
    Su, Wu-Chou
    Sandoval-Tan, Jennifer
    Chiou, Tzeon-Jye
    Jin, Kate
    Hsu, Chiun
    Cheng, Ann-Lii
    ONCOLOGY, 2013, 85 (01) : 44 - 52
  • [24] Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib
    Terashima, Takeshi
    Kido, Hidenori
    Takata, Noboru
    Hayashi, Tomoyuki
    Seki, Akihiro
    Nakagawa, Hidetoshi
    Nio, Kouki
    Toyama, Tadashi
    Iida, Noriho
    Yamada, Shinya
    Shimakami, Tetsuro
    Takatori, Hajime
    Arai, Kuniaki
    Yamashita, Tatsuya
    Mizukoshi, Eishiro
    Yamashita, Taro
    CANCERS, 2025, 17 (02)
  • [25] A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
    Yopp, A.
    Zhu, H.
    Mansour, J.
    Singal, A.
    Arriaga, Y.
    Beg, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S34 - S35
  • [26] A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [27] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Renouf, Daniel J.
    Welch, Stephen
    Moore, Malcolm J.
    Krzyzanowska, Monika K.
    Knox, Jennifer
    Feld, Ronald
    Liu, Geoffrey
    MacKay, Helen
    Petronis, Jennifer
    Wang, Lisa
    Chen, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1339 - 1344
  • [28] A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Daniel J. Renouf
    Stephen Welch
    Malcolm J. Moore
    Monika K. Krzyzanowska
    Jennifer Knox
    Ronald Feld
    Geoffrey Liu
    Helen MacKay
    Jennifer Petronis
    Lisa Wang
    Eric Chen
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1339 - 1344
  • [29] Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
    Kozuch, Peter
    Malamud, Steve
    Wasserman, Carrie
    Homel, Peter
    Mirzoyev, Takhir
    Grossbard, Michael
    CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 38 - 42
  • [30] Updated results from phase II study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
    Zhang, H.
    Lu, W.
    Fu, Y.
    Li, J.
    Wang, J.
    Chen, Z.
    Ding, S.
    Chen, S.
    Huang, J.
    Zhai, J.
    Li, X.
    Yang, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1486 - S1486
12345